Physicochemical and toxicological characterization of sucrose-bound polynuclear iron oxyhydroxide formulations

Journal of Pharmaceutical Investigation

Volumn 45, Issue 1, 2015, Pages 35-49

  Barot, Bhavesh S ^a   Parejiya, Punit B ^a   Shelat, Pragna K ^a   Shah, Gaurang B ^a   Mehta, Dharmik M ^a   Pathak, Trupti V ^b  

^a K B INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH   (India)

^b Claris Lifesciences Ltd   (India)

Author keywords

Iron sucrose complex; Labile iron; Raman spectroscopy; Toxicology; Venofer ; X ray diffractometry

Indexed keywords

FERRIC HYDROXIDE; IRON SACCHARATE; SUCROSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATOMIC FORCE MICROSCOPY; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; CHEMICAL ANALYSIS; CHEMICAL REACTION KINETICS; CONTROLLED STUDY; ELEMENTAL ANALYSIS; FEMALE; GEL PERMEATION CHROMATOGRAPHY; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LIGHT SCATTERING; MALE; MICROSCOPY; MOLECULAR WEIGHT; MOSSBAUER SPECTROSCOPY; NONHUMAN; OXIDATIVE STRESS; PH; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; QUANTITATIVE ASSAY; RAMAN SPECTROMETRY; RAT; SAMPLING; TOXICOLOGY; TRANSMISSION ELECTRON MICROSCOPY; X RAY DIFFRACTION;

EID: 84923673541     PISSN: 20935552     EISSN: 20936214     Source Type: Journal    
DOI: 10.1007/s40005-014-0143-2     Document Type: Article

References (50)

1. Agarwal R, Rizkala AR, Bastani B, Kaskas MO, Leehey DJ, Besarab A (2006) A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol 26(5):445–454. doi:10.1159/000096174
2. Auerbach M, Ballard H (2008a) Intravenous iron as standard of care in oncology: opportunity lost. J Am Pharm Assoc 48(4):455–457. doi:10.1331/JAPhA.2008.08532
3. Auerbach M, Ballard H (2008b) Intravenous iron in oncology. J Natl Compr Canc Netw 6(6):585–592 quiz 592
4. Balakrishnan VS, Rao M, Kausz AT, Brenner L, Pereira BJ, Frigo TB, Lewis JM (2009) Physicochemical properties of ferumoxytol, a new intravenous iron preparation. Eur J Clin Invest 39(6):489–496. doi:10.1111/j.1365-2362.2009.02130.x
5. Barot BS, Parejiya PB, Mehta DM, Shelat PK, Shah GB (2014) Physicochemical and structural characterization of iron–sucrose formulations: a comparative study. Pharm Dev Technol 19(5):513–520. doi:10.3109/10837450.2013.795171
6. Binner JGP, Santacruz MI, Annapoorani K (2009) Method for concentrating nanosuspensions. US Patent US 2009/0294357 A1
7. Breymann C, Richter C, Huttner C, Huch R, Huch A (2000) Effectiveness of recombinant erythropoietin and iron sucrose vs. iron therapy only, in patients with postpartum anaemia and blunted erythropoiesis. Eur J Clin Invest 30(2):154–161
8. Breymann C, Bian XM, Blanco-Capito LR, Chong C, Mahmud G, Rehman R (2011) Expert recommendations for the diagnosis and treatment of iron-deficiency anemia during pregnancy and the postpartum period in the Asia-Pacific region. J Perinat Med 39(2):113–121. doi:10.1515/JPM.2010.132
9. Cancado RD, Munoz M (2011) Intravenous iron therapy: how far have we come? Rev Bras Hematol Hemoter 33(6):461–469. doi:10.5581/1516-8484.20110123
10. Carter P (1971) Spectrophotometric determination of serum iron at the submicrogram level with a new reagent (ferrozine). Anal Biochem 40(2):450–458
11. Danielson BG (2004) Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol 15(Suppl 2):S93–S98. doi:10.1097/01.ASN.0000143814.49713.C5
12. de Faria DLA, Venâncio Silva S, de Oliveira MT (1997) Raman microspectroscopy of some iron oxides and oxyhydroxides. J Raman Spectros 28(11):873–878. doi:10.1002/(sici)1097-4555(199711)28
13. Elford P, Bouchard J, Jaillet L, Pearson N, Rogue A, Sabadie C, Forster R (2013) Biodistribution and predictive hepatic gene expression of intravenous iron sucrose. J Pharmacol Toxicol Methods 68(3):374–383. doi:10.1016/j.vascn.2013.04.005
14. Erni I, Oswald N, Rich HW, Schneider W (1984) Chemical characterization of iron (III)-hydroxide-dextrin complexes. A comparative study of commercial preparations with alleged reproductions used in the examination of bioavailability. Arzneimittelforschung 34(11):1555–1559
15. Esposito BP, Breuer W, Slotki I, Cabantchik ZI (2002) Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients. Eur J Clin Invest 32(Suppl 1):42–49
16. Fishbane S (2003) Safety issues with iron sucrose. Am J Kidney Dis 41(4):899 author reply 900
17. Funk F, Long GJ, Hautot D, Büchi R, Christl I, Weidler PG (2001) Physical and chemical characterization of therapeutic iron containing materials: a study of several superparamagnetic drug formulations with the β-FeOOH or ferrihydrite structure. Hyperfine Interact 136–137(1–2):73–95. doi:10.1023/a:1015552311359
18. Futterer S, Andrusenko I, Kolb U, Hofmeister W, Langguth P (2013) Structural characterization of iron oxide/hydroxide nanoparticles in nine different parenteral drugs for the treatment of iron deficiency anaemia by electron diffraction (ED) and X-ray powder diffraction (XRPD). J Pharm Biomed Anal 86:151–160. doi:10.1016/j.jpba.2013.08.005
19. Garcia-Erce JA, Cuenca J, Martinez F, Cardona R, Perez-Serrano L, Munoz M (2006) Perioperative intravenous iron preserves iron stores and may hasten the recovery from post-operative anaemia after knee replacement surgery. Transfus Med 16(5):335–341. doi:10.1111/j.1365-3148.2006.00682.x
20. Geisser P, Baer M, Schaub E (1992) Structure/histotoxicity relationship of parenteral iron preparations. Arzneimittelforschung 42(12):1439–1452
21. Giannini EG, Testa R, Savarino V (2005) Liver enzyme alteration: a guide for clinicians. Can Med Assoc J 172(3):367–379. doi:10.1503/cmaj.1040752
22. Gibbs CR (1976) Characterization and application of FerroZine iron reagent as a ferrous iron indicator. Anal Chem 48(8):1197–1201. doi:10.1021/ac50002a034
23. Hanesch M (2009) Raman spectroscopy of iron oxides and (oxy)hydroxides at low laser power and possible applications in environmental magnetic studies. Geophys J Int 177:941–948. doi:10.1111/j.1365-246X.2009.04122.x
24. Horl WH (2007) Clinical aspects of iron use in the anemia of kidney disease. J Am Soc Nephrol 18(2):382–393. doi:10.1681/ASN.2006080856
25. Huwe H, Fröba M (2003) Iron (III) oxide nanoparticles within the pore system of mesoporous carbon CMK-1: intra-pore synthesis and characterization. Microporous Mesoporous Mater. 60(1–3):151–158. doi:10.1016/S1387-1811(03)00336-6
26. Jahn MR, Andreasen HB, Futterer S, Nawroth T, Schunemann V, Kolb U, Hofmeister W, Munoz M, Bock K, Meldal M, Langguth P (2011) A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm 78(3):480–491. doi:10.1016/j.ejpb.2011.03.016
27. Johnson CA, Mason NA, Bailie GR (1999) Intravenous iron products. ANNA J 26(5):522–524
28. Kudasheva DS, Lai J, Ulman A, Cowman MK (2004) Structure of carbohydrate-bound polynuclear iron oxyhydroxide nanoparticles in parenteral formulations. J Inorg Biochem 98(11):1757–1769. doi:10.1016/j.jinorgbio.2004.06.010
29. Langford JI, Wilson AJC (1978) Scherrer after sixty years: a survey and some new results in the determination of crystallite size. J Appl Crystallogr 11(2):102–113
30. Lim PS, Wei YH, Yu YL, Kho B (1999) Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant 14(11):2680–2687
31. Madore F, White CT, Foley RN, Barrett BJ, Moist LM, Klarenbach SW, Culleton BF, Tonelli M, Manns BJ (2008) Clinical practice guidelines for assessment and management of iron deficiency. Kidney Int Suppl 110:S7–S11. doi:10.1038/ki.2008.269
32. Maher P, Lewerenz J, Lozano C, Torres JL (2008) A novel approach to enhancing cellular glutathione levels. J Neurochem 107(3):690–700. doi:10.1111/j.1471-4159.2008.05620.x
33. Meier T, Schropp P, Pater C, Leoni AL, Khov-Tran VV, Elford P (2011) Physicochemical and toxicological characterization of a new generic iron sucrose preparation. Arzneimittelforschung 61(2):112–119. doi:10.1055/s-0031-1296176
34. Mimic-Oka J, Savic-Radojevic A, Pljesa-Ercegovac M, Opacic M, Simic T, Dimkovic N, Simic DV (2005) Evaluation of oxidative stress after repeated intravenous iron supplementation. Ren Fail 27(3):345–351
35. Munoz M, Breymann C, Garcia-Erce JA, Gomez-Ramirez S, Comin J, Bisbe E (2008) Efficacy and safety of intravenous iron therapy as an alternative/adjunct to allogeneic blood transfusion. Vox Sang 94(3):172–183. doi:10.1111/j.1423-0410.2007.01014.x
36. Munoz M, Gomez-Ramirez S, Garcia-Erce JA (2009) Intravenous iron in inflammatory bowel disease. World J Gastroenterol 15(37):4666–4674
37. NICE-guidelines (2008) Chronic kidney disease—national clinical guidelines for early identification and management in adults in primary and secondary care. National Institute of Health and Clinical Excellence, London
38. Rahman I, MacNee W (2000) Oxidative stress and regulation of glutathione in lung inflammation. Eur Respir J 16(3):534–554
39. Rennie IDB, Keen H, Cowhig J, Harvey M, Field M, Quartey E (1967) Evaluation of clinical methods for detecting proteinuria. Lancet 290(7514):489–492. doi:10.1016/S0140-6736(67)91656-X
40. Roob JM, Khoschsorur G, Tiran A, Horina JH, Holzer H, Winklhofer-Roob BM (2000) Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 11(3):539–549
41. Sengolge G, Horl WH, Sunder-Plassmann G (2005) Intravenous iron therapy: well-tolerated, yet not harmless. Eur J Clin Invest 35(Suppl 3):46–51. doi:10.1111/j.1365-2362.2005.01530.x
42. Slavov L, Abrashev MV, Merodiiska T, Gelev CH, Vandenberghe RE, Markova-Deneva I, Nedkov I (2010) Raman spectroscopy investigation of magnetite nanoparticles in ferrofluids. J Magn Magn Mater 322(14):1904–1911. doi:10.1016/j.jmmm.2010.01.005
43. Toblli JE, Cao G, Oliveri L, Angerosa M (2009a) Differences between original intravenous iron sucrose and iron sucrose similar preparations. Arzneimittelforschung 59(4):176–190. doi:10.1055/s-0031-1296383
44. ®, and potential implications. Port J Nephrol Hypertens 23(1):53–63
45. ®. Center for Drug Evaluation and Research Application No 21-135
46. USP (2006) Iron sucrose injection monograph, 29 ed. United States Pharmacopeia 29-National Formulary 24, USP Convention, Rockville
47. Van Wyck D, Anderson J, Johnson K (2004) Labile iron in parenteral iron formulations: a quantitative and comparative study. Nephrol Dial Transplant 19(3):561–565
48. Zager RA (2006) Parenteral iron compounds: potent oxidants but mainstays of anemia management in chronic renal disease. Clin J Am Soc Nephrol 1(Suppl 1):S24–S31. doi:10.2215/CJN.01410406
49. Zager RA, Johnson AC, Hanson SY, Lund S (2005) Parenteral iron compounds sensitize mice to injury-initiated TNF-alpha mRNA production and TNF-alpha release. Am J Physiol Renal Physiol 288(2):F290–F297. doi:10.1152/ajprenal.00342.2004
50. Zboril R, Mashlan M, Petridis D (2002) Iron(III) oxides from thermal processes synthesis, structural and magnetic properties, Mossbauer spectroscopy characterization, and applications. Chem Mater 14:969–982